- ICH GCP
- US Clinical Trials Registry
- Search trials
Search clinical trials for: Postmenopausal Women with Hormone Receptor-Positive Locally Advanced Breast Cancer
Total 242709 results
-
Massachusetts General HospitalNational Cancer Institute (NCI); Dana-Farber Cancer Institute; AstraZeneca; Brigham...CompletedHead and Neck CancerUnited States
-
Centre Francois BaclesseNational Cancer Institute, France; ARC Foundation for Cancer ResearchTerminatedMetastatic Breast Cancer | PostmenopausalFrance
-
Massachusetts General HospitalMerck Sharp & Dohme LLC; Dana-Farber Cancer Institute; Brigham and Women's HospitalTerminatedPancreatic Cancer | Adenocarcinoma of the PancreasUnited States
-
Georgetown UniversityTerminatedBreast Cancer | Neoplasms, Breast | Cancer of the BreastUnited States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER2/Neu Over-expressing Locally Advanced Breast CancerChina, United States, France, Hungary, Turkey, Japan, Germany, Singapore, Italy, Poland, Spain, United Kingdom, Thailand, Israel, Australia, Belgium, Greece, Argentina, Czech Republic, Mexico, Slovakia
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Massachusetts General HospitalNovartis; Dana-Farber Cancer InstituteTerminatedBreast CancerUnited States
-
Novartis PharmaceuticalsUniversity of Sheffield; Danish Breast Cancer Cooperative GroupCompletedHormone Sensitive Resected Primary Breast Cancer in Postmenopausal WomenDenmark, United Kingdom
-
NovartisCompleted
-
Novartis PharmaceuticalsCompletedBreast CancerUnited Kingdom
-
National Cancer Institute (NCI)TerminatedStage IV Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Cancer Institute and Hospital, Chinese Academy...Unknown
-
Washington University School of MedicineNational Cancer Institute (NCI)Completed
-
Merrimack PharmaceuticalsSanofiCompletedLocally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer, | Primary Peritoneal Cancer or Endometrial Cancer | Locally Advanced/Metastatic Her2 Non Overexpressing Breast CancerUnited States
-
Altor BioScienceCompletedMalignant Solid Tumour | Locally Advanced Malignant NeoplasmUnited States
-
Cancer Research UKCompletedBreast Cancer | Ovarian Cancer | brca1 Mutation Carrier | brca2 Mutation CarrierUnited Kingdom
-
Novartis PharmaceuticalsCompletedBreast CancerChina, United States, Belgium, Germany, Italy, Austria, Japan, Australia, Canada, Sweden, Switzerland, United Kingdom, Spain, Denmark, France, Ireland, Israel, Netherlands, Korea, Republic of, Norway
-
Mayo ClinicNational Cancer Institute (NCI)Terminated
-
King Faisal Specialist Hospital & Research CenterCompleted
-
PfizerCompletedBreast CancerKorea, Republic of
-
The University of Texas Medical Branch, GalvestonWithdrawn
-
University of PittsburghAventis Pharmaceuticals; Procter and GambleCompleted
-
Ohio State University Comprehensive Cancer CenterPfizerCompleted
-
National Cancer Institute (NCI)TerminatedStage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | HER2/Neu Negative | Male Breast CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | Male Breast Carcinoma | Adult Solid NeoplasmUnited States
-
UNICANCERCompleted
-
Hoffmann-La RocheCompletedBreast CancerSpain, Russian Federation, Austria, Italy, Germany, Portugal
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)Terminated
-
PfizerTerminatedEarly Breast Cancer (Phase 2) | Advanced Breast Cancer (Phase 1b)Spain, Sweden, Italy, Belgium
-
National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast CancerUnited States
-
National Cancer Institute (NCI)CompletedStage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast CancerUnited States
-
PfizerInternational Collaborative Cancer GroupCompletedBreast NeoplasmsAustralia, Denmark, Netherlands, United States, Bulgaria, Hungary, Italy, Spain, Belgium, Czech Republic, Ireland, Poland, Russian Federation, Sweden, United Kingdom, Croatia, Serbia, Germany, Bosnia and Herzegovina, Norway, South... and more
-
Intarcia TherapeuticsTerminatedToremifene With or Without Atamestane in Treating Postmenopausal Women With Metastatic Breast CancerBreast CancerUnited States
-
Novartis PharmaceuticalsCompleted
-
AstraZenecaCompletedBreast Cancer | PostmenopauseGermany
-
UNICANCERCompleted
-
International Collaborative Cancer GroupEuropean Organisation for Research and Treatment of Cancer - EORTC; UNICANCERUnknownBreast CancerFrance, Belgium, United Kingdom
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI)Completed
-
ImunonUnknown
-
International Collaborative Cancer GroupUnknownBreast CancerUnited Kingdom
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Unknown
-
Ontario Clinical Oncology Group (OCOG)AstraZenecaCompleted
-
Scottish Cancer Therapy NetworkCompleted
-
Scottish Cancer Therapy NetworkUnknown
-
European Organisation for Research and Treatment...Swiss Group for Clinical Cancer Research; Swedish Breast Cancer Group; Anglo...CompletedBreast CancerFrance, Switzerland, Poland, Sweden, Belgium, Netherlands, United Kingdom, Portugal, Slovenia
-
Gruppo Italiano Mammella (GIM)Unknown
-
Washington University School of MedicineNovartis; PfizerCompletedBreast NeoplasmsUnited States
-
Imperial College LondonCompletedBreast CancerUnited Kingdom, Korea, Republic of
-
Institut Català d'OncologiaUnknown
-
University of SheffieldUnknownBreast Cancer | Metastatic Cancer